Search results
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Zacks via Yahoo Finance· 2 days agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
FDA Approves Boehringer Ingelheim’s CYLTEZO® Biosimilar to Humira for Multiple Chronic Inflammatory...
JD Supra· 4 days agoCYLTEZO was first approved in the US in 2017 and later approved in the US as an interchangeable biosimilar to Humira in October 2021. A lower concentration version of CYLTEZO (50 mg/mL) has been on the market since July 2023.
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? | The Motley...
The Motley Fool· 4 days agoWall Street is feeling pretty good about AbbVie's (ABBV -1.19%) performance in 2024 so far. Chen...
Earnings call: Alvotech raises 2024 guidance amid strong biosimilar push By Investing.com
Investing.com· 2 days agoDuring their recent earnings call, the company's executives highlighted significant strides in the...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 3 days agoTakeaway Humira was one of the first biologic medications approved for psoriatic arthritis in 2005...
This Is What Whales Are Betting On AbbVie - AbbVie (NYSE:ABBV)
Benzinga· 2 days agoDate Ask Bid Price Strike Price Total Trade Price Open Interest Volume ABBV PUT SWEEP BEARISH 11/15/24 $7.7 $7... 1.0K About AbbVie AbbVie ...
Patent reform could be the next big move to help bring down drug prices
Axios· 3 days agoAfter pitched battles over Medicare drug price negotiations, Congress may be pivoting to more...
Senators Mull Ways to Stop Patent 'Abuse' by Pharma Companies
MedPage Today· 4 days ago"Too often the prices charged by Big Pharma do not reflect a scientific advancement," argued Sen....
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
InvestorPlace· 4 days agoSince 1928, there have been 25 bear markets, or declines in the S&P 500 of 20% or more, according to...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 19 hours agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...